CTOs on the Move

World Heart Corporation

www.worldheart.com

 
World Heart Corporation is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.worldheart.com
  • 4750 Wiley Post Way Ste 120
    Salt Lake City, UT USA 84116
  • Phone: 801.355.6255

Executives

Name Title Contact Details

Similar Companies

Hudson Optical

Hudson Optical is a Henderson, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mexpo International

Mexpo International is a Hayward, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ATF Medical

ATF Medical is a nationwide leading provider of complex rehab technology, power mobility and home accessibility products, home modifications, and electrotherapy equipment. Our goal is to help our customers achieve better quality of life by providing superior products, dependability, and customer service. We are a nationally accredited durable medical equipment provider offering competitive pricing, comprehensive assistance, and a support staff available to answer any questions you may have. We help our clients obtain the best medical equipment to meet their needs.

Instromedix dba: LifeWatch

Instromedix dba: LifeWatch is a Des Plaines, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Motif Neurotech

Motif Neurotech is a clinical-stage company leading the development of minimally invasive neuromodulation therapeutics for mental health. The company`s lead product, for treatment resistant depression (TRD), is a miniature implant that is designed to treat TRD by increasing activity in the prefrontal cortex. Studies over 20 years show stimulation of the pre-frontal cortex effectively treats treatment resistant depression without the side effects of anti-depressants. However, existing brain stimulation treatments like transcranial magnetic stimulation (TMS) can be expensive and challenging for patients to access, with daily treatments required for six weeks that may need to be repeated. Human and large animal studies show Motif`s prototype stimulates target brain areas like TMS, and the company is preparing to begin clinical trials of their first chronic implants in 2025. Motif`s implant is enabled by patent-pending wireless magnetoelectric power transfer developed at Rice University. Motif`s founders and key team members are clinical, medical device and academic experts with over 5,000 surgical procedures and decades of medical device experience.